Argireline
Cosmetic signal peptide
A hexapeptide studied in cosmetic muscle-relaxation research.
Overview
Argireline is a trade name for acetyl hexapeptide-8 (also called acetyl hexapeptide-3), a synthetic cosmetic peptide developed by Lipotec for topical anti-wrinkle use. It is designed to mimic the N-terminal end of the SNAP-25 protein.
At a glance
What Argireline does
Argireline (Acetyl Hexapeptide-8, formerly acetyl hexapeptide-3) is a synthetic six-amino-acid peptide developed by the Spanish lab Lipotec (now Lubrizol) and is the original 'topical Botox' cosmetic peptide. Its purpose is to reduce the appearance of dynamic expression wrinkles by dampening the facial-muscle contractions that etch them in, using a mechanism that mimics — but is chemically unrelated to — botulinum toxin.
Mechanistically, Argireline reproduces the N-terminal sequence of SNAP-25, one of the three proteins (with syntaxin and VAMP/synaptobrevin) that form the SNARE complex responsible for fusing acetylcholine vesicles at the presynaptic membrane. By competing with native SNAP-25, Argireline slightly destabilizes SNARE assembly, so vesicles release less neurotransmitter and the neuromuscular signal to contract is blunted. The result is relaxation of the small muscles of facial expression and reduced creasing of the overlying skin — without the vesicle-protein cleavage and muscle paralysis Botox produces. Some formulations also claim mild effects on catecholamine release.
The evidence is a set of small cosmetic-science and manufacturer-linked studies (e.g., Blanes-Mira 2002 and later trials) reporting reduced wrinkle depth and a strong safety/low-irritation record; the CIR panel has assessed it as safe for cosmetic use. The most important caveat is delivery: an in-vitro penetration study found that over 99% of applied Argireline failed to reach the dermis, with only a tiny fraction detected in the viable epidermis — so whether topically applied Argireline actually reaches neuromuscular junctions in living skin remains unproven. It is a topical cosmetic ingredient, not an injectable.
Effects reported in research
- Reproduces the N-terminal end of SNAP-25 and competitively destabilizes the SNARE complex (in-vitro mechanism).
- Blunts acetylcholine release at the neuromuscular junction, relaxing small facial-expression muscles.
- Reduces the appearance of dynamic expression wrinkles (forehead, crow's feet, frown lines) in cosmetic studies.
- Reported reductions in wrinkle depth in small cosmetic-science trials (e.g., Blanes-Mira 2002 and follow-ups).
- Does not cleave SNAP-25 or paralyze muscle — a modulatory, reversible action distinct from botulinum toxin.
- Well-documented low-irritation safety profile; assessed as safe for cosmetic use by the CIR panel.
- Major limitation: an in-vitro study found >99% failed to penetrate to the dermis, questioning whether it reaches its target in vivo.
- Used topically as a cosmetic ingredient only — not injected and not a clinical therapeutic.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Argireline is a topical hexapeptide modeled on the N-terminus of SNAP-25, a component of the SNARE complex that mediates vesicle docking and neurotransmitter release. By competing with SNAP-25 in SNARE complex assembly in its proposed mechanism, it is intended to attenuate signaling that drives facial-muscle contraction, thereby softening the appearance of expression lines. It is often described as a topical, cosmetic-strength analog to the neuromuscular effect of botulinum toxin, though supporting data are largely cosmetic/supplier-derived.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Argireline appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Cosmetic ingredient (INCI: Acetyl Hexapeptide-8), not a drug.
- Modeled on the N-terminal region of SNAP-25.
- Proposed to interfere with SNARE-complex-mediated neurotransmitter release.
- Applied topically in leave-on skincare.
- SNAP-8 is a longer octapeptide analog marketed as an extension of the same concept.
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Argireline is a research compound.
Argireline is a topical cosmetic peptide, so reported use is a formulation percentage rather than an injected dose. These are reference figures for research context only, not human dosing guidance.
- Active topical formulation: ~5%-10% acetyl hexapeptide-8
- Clinical-strength reference: 10% (a cited study reported ~30% wrinkle-depth reduction over 30 days)
Effect magnitude varies with concentration, vehicle, and treated area; skin-penetration of the ~889 Da peptide is debated.
How it compares
Argireline is the original SNAP-25-mimicking hexapeptide; SNAP-8 is its elongated analog, and both differ from collagen-signaling matrikines like Matrixyl.
Commonly studied alongside
Compounds frequently researched together with Argireline in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Argireline sits in the Cosmetic & Dermal area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source Argireline
For researchers studying Argireline, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.
Frequently asked questions
What is Argireline?
Argireline is the trade name for acetyl hexapeptide-8 (also historically called acetyl hexapeptide-3), a synthetic six-amino-acid topical cosmetic peptide. Its sequence, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, mimics the N-terminal end of the SNAP-25 protein.
How does Argireline work?
Argireline is proposed to interfere with the SNARE complex needed for neurotransmitter (acetylcholine) release, which in cosmetic framing is described as modestly reducing the facial-muscle contractions that form expression lines. It is sometimes described as a topical, far milder analogy to botulinum toxin's mechanism.
What topical concentration of Argireline is used?
Cosmetic formulations commonly use 5%-10% active peptide, with 10% being the most-referenced clinical-strength level. A frequently cited study reported up to ~30% reduction in wrinkle depth after 30 days of use at a 10% concentration.
How does Argireline differ from SNAP-8?
SNAP-8 is an extended eight-residue analog built from the same active motif as Argireline's six residues. Formulation literature reports SNAP-8 as somewhat more active in certain assays, but both share the same SNARE-interference mechanism and topical use.
Is skin penetration a concern for Argireline?
Yes, it is actively debated. At ~889 Da the molecule is relatively large, and some researchers question how much crosses the stratum corneum, while others point to positive clinical readouts as evidence of sufficient penetration to act. Formulation vehicle strongly influences delivery.
Is Argireline injected?
No. Argireline is a topical cosmetic ingredient, not an injectable drug, and is not FDA-approved to treat any condition.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.